Therefore, hepatocyte Caspase-8 is critical for the pathogenesis of steatohepatitis, drugs targeting Caspase-8 might be a plausible treatment for NAFLD/NASH [39]. This evidence concerns the gene CASP8 and metabolic dysfunction-associated steatotic liver disease.